Synthesis of fluorinated carbocyclic pyrimidine nucleoside analogues
Analogues of the canonical nucleosides have a longstanding presence and proven capability within medicinal chemistry and drug discovery research. The synthesis reported herein successfully replaces furanose oxygen with CF 2 and CHF in pyrimidine nucleosides, granting access to an alternative pharmac...
Gespeichert in:
Veröffentlicht in: | Organic & biomolecular chemistry 2022-12, Vol.2 (47), p.9469-9489 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Analogues of the canonical nucleosides have a longstanding presence and proven capability within medicinal chemistry and drug discovery research. The synthesis reported herein successfully replaces furanose oxygen with CF
2
and CHF in pyrimidine nucleosides, granting access to an alternative pharmacophore space. Key diastereoselective conjugate addition and fluorination methodologies are developed from chiral pool materials, establishing a robust gram-scale synthesis of 6′-(
R
)-monofluoro- and 6′-
gem
-difluorouridines. Vital intermediate stereochemistries are confirmed using X-ray crystallography and NMR analysis, providing an indicative conformational preference for these fluorinated carbanucleosides. Utilising these 6′-fluorocarbauridine scaffolds enables synthesis of related cytidine, ProTide and 2′-deoxy analogues alongside a preliminary exploration of their biological capabilities in cancer cell viability assays. This synthetic blueprint offers potential to explore fluorocarbanucleoside scaffolds, indicatively towards triphosphate analogues and as building blocks for oligonucleotide synthesis.
Synthesis of 6′-fluorinated carbauridine scaffolds enables access to related cytidine, ProTide and 2′-deoxy analogues, alongside preliminary exploration of their biological capabilities in cancer cell viability assays. |
---|---|
ISSN: | 1477-0520 1477-0539 |
DOI: | 10.1039/d2ob01761j |